- A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Program of Integrative Medicine, Department of Cardiology, Beijing University of Chinese Medicine, Beijing, China; and Harvard Stem Cell Institute, Harvard University, Cambridge, MA has reported that “Loss of MicroRNA-155 Protects the Heart From Pathological Cardiac Hypertrophy.”
- This study was published in the 09 May 2014 Circulation Research by Prof. Wang and others from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Program of Integrative Medicine, Department of Cardiology, Beijing University of Chinese Medicine, Beijing, China; and Harvard Stem Cell Institute, Harvard University, Cambridge, MA.
- On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Treating cardiac hypertrophy and heart failure with Vitamins: 1,25-dihydroxyvitamin D protects the heart from cardiac hypertrophy & heart failure via down regulation of its target gene. This study suggests that 1,25-dihydroxyvitamin D, by suppressing the expression of its target gene, it could protect the heart from pathological cardiac hypertrophy and heart failure. Together, this study suggests that pharmacological formulations containing “1,25-dihydroxyvitamin D” can be used to treat Cardiac hypertrophy and heart failure.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Treating cardiac hypertrophy and heart failure with Vitamins: 1,25-dihydroxyvitamin D protects the heart from cardiac hypertrophy & heart failure via down regulation of its target gene, 12/June/2014, 9.47 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
